BTAI · BioXcel Therapeutics, Inc.
$0.89
-0.30 (-25.21%)
At close · Aug 17
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's history of significant losses, its negative cash flows from operations, its current debt obligations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management's assessment that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report. Although the Company has developed and implemented certain plans, they will not mitigate the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$28.59M
Shares
31.31M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer | $1,119,245 |
| Javier Rodriguez | Senior VP and Chief Legal Officer | $1,012,552 |
| Richard Steinhart | SVP and Chief Financial Officer | $998,216 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer | $4,731,147 |
| Matthew Wiley | SVP and Chief Commercial Officer | $1,264,394 |
| Javier Rodriguez | Senior VP and Chief Legal Officer | $1,121,943 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer | $4,559,195 |
| Matthew Wiley | SVP and Chief Commercial Officer | $1,927,697 |
| Javier Rodriguez | Senior VP and Chief Legal Officer | $1,218,539 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer | $9,372,177 |
| Javier Rodriquez | Senior Vice President and Chief Legal Officer | $2,014,426 |
| Javier Rodriguez | Senior VP and Chief Legal Officer | $2,014,426 |
| Frank Yocca | Senior Vice President and Chief Scientific Officer | $1,153,469 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer and President | $9,576,550 |
| William P. Kane | Executive Vice President and Chief Commercial Officer | $4,569,654 |
| Reina Benabou | M.D., Ph.D. Senior Vice President and Chief Development Officer | $2,736,184 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | Chief Executive Officer and President | $1,968,931 |
| Vincent O’Neill | Chief Medical Officer | $510,167 |
| Richard Steinhart | Chief Financial Officer | $403,997 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vimal Mehta | President and Chief Executive Officer | $701,609 |
| Vincent O’Neill | Chief Medical Officer | $663,301 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Rajiv Patni | Class II director | Appointed | 2025-01-16 |
| Matt Wiley | Chief Commercial Officer | Terminated | 2024-09-19 |
| Sandeep ("Steve") Laumas, M.D. | Class II director | Resigned | 2023-09-25 |
| Krishnan Nandabalan, Ph.D. | member of the Company's Board of Directors | Resigned | 2023-09-25 |
| Michael Miller | Audit Committee | Appointed | 2022-07-05 |
| Michael Miller | Class II director | Appointed | 2022-07-05 |
| William P. Kane, Jr. | Executive Vice President and Chief Commercial Officer | Resigned | 2021-10-13 |
Key facts
CIK
1720893
CUSIP
09075P204
13F (30d)
46 filings
46 filers
Visit website
Investor relations